Over the last 30 years, optimization of CHO biotherapeutic expression systems and processes has realized dramatic advances in key performance attributes such as titers. By leveraging high throughput systems for clone generation and screening, the chances of isolating high productivity clones can be increased and timelines to IND shortened.
But what makes a next-generation CHO bioproduction process?
With a focus on DNA and cell expression technologies, Lonza’s Dr. Peter O’Callaghan takes a journey through some areas of innovation for creating the expression systems of the future. He explains how Lonza has harnessed genomics and genome engineering to generate the GS Effex® cell line for enhanced antibody effector function - the latest addition to the GS Gene Expression System®.